China Dominates APAC’s Emergence As Global Trials Hub

39% Of Total Trial Starts In ’23

Asia-Pacific continues to solidify its position as a key location for clinical trials, with China in particular dominating such activity in the region, and increasingly globally, a Citeline White Paper shows.

APAC
China dominates APAC clinical trials activity • Source: Shutterstock

The APAC region has emerged as a leader in the global clinical trial landscape, attributable to several key factors including a large, diverse patient population with a large proportion of treatment-naïve people, cost effectiveness in conducting clinical trials and a favorable regulatory environment.

So concludes a new White Paper from Citeline Clinical,

More from Global Vision

More from Market Intelligence